Abstract
IL-17A is a T cell–specific cytokine1 that is involved in chronic inflammations, such as Mycobacterium infection2, Crohn's disease3, rheumatoid arthritis4 and multiple sclerosis5. Mouse models have explained the molecular basis of IL-17A production6,7 and have shown that IL-17A has a positive effect not only on granuloma formation8 and neurodegeneration9 through unknown mechanisms, but also on bone resorption through Receptor activator of NF-κB ligand (RANKL) induction in osteoblasts4,10. Langerhans cell histiocytosis (LCH) is a rare disease of unknown etiology, lacking an animal model, that cumulates symptoms that are found separately in various IL-17A–related diseases, such as aggressive chronic granuloma formation, bone resorption and soft tissue lesions with occasional neurodegeneration11,12. We examined IL-17A in the context of LCH and found that there were high serum levels of IL-17A during active LCH and unexpected IL-17A synthesis by dendritic cells (DCs), the major cell type in LCH lesions. We also found an IL-17A–dependent pathway for DC fusion, which was highly potentiated by IFN-γ and led to giant cells expressing three major tissue-destructive enzymes: tartrate resistant acidic phosphatase and matrix metalloproteinases 9 and 12. IFN-γ expression has been previously documented in LCH13 and observed in IL-17A–related diseases14,15,16,17. Notably, serum IL-17A–dependent fusion activity correlates with LCH activity. Thus, IL-17A and IL-17A–stimulated DCs represent targets that may have clinical value in the treatment of LCH and other IL-17A–related inflammatory disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yao, Z. et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811–821 (1995).
Lockhart, E., Green, A.M. & Flynn, J.L. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol. 177, 4662–4669 (2006).
Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345–1352 (1999).
Vaknin-Dembinsky, A., Balashov, K. & Weiner, H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176, 7768–7774 (2006).
Ivanov, I.I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006).
Zhou, L. et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).
Umemura, M. et al. IL-17–mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 178, 3786–3796 (2007).
Komiyama, Y. et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566–573 (2006).
Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673–2682 (2006).
Beverley, P.C., Egeler, R.M., Arceci, R.J. & Pritchard, J. The Nikolas Symposia and histiocytosis. Nat. Rev. Cancer 5, 488–494 (2005).
Grois, N., Prayer, D., Prosch, H. & Lassmann, H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 128, 829–838 (2005).
Egeler, R.M., Favara, B.E., van Meurs, M., Laman, J.D. & Claassen, E. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94, 4195–4201 (1999).
Cruz, A. et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17–producing CD4 T cells during mycobacterial infection. J. Immunol. 177, 1416–1420 (2006).
Suryani, S. & Sutton, I. An interferon-γ–producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J. Neuroimmunol. 183, 96–103 (2007).
Aarvak, T., Chabaud, M., Miossec, P. & Natvig, J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells, but not by Th2 cells. J. Immunol. 162, 1246–1251 (1999).
Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849–1861 (2007).
Wilson, N.J. et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nat. Immunol. 8, 950–957 (2007).
Wolk, K. et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J. Immunol. 178, 5973–5981 (2007).
Annels, N.E. et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J. Exp. Med. 197, 1385–1390 (2003).
Laman, J.D., Leenen, P.J., Annels, N.E., Hogendoorn, P.C. & Egeler, R.M. Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol. 24, 190–196 (2003).
Rivollier, A. et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104, 4029–4037 (2004).
Sato, N.E. et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J. Exp. Med. 197, 1385–1390 (2003).
da Costa, C.E. et al. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J. Exp. Med. 201, 687–693 (2005).
Rust, R. et al. Gene expression analysis of dendritic/Langerhans cells and Langerhans cell histiocytosis. J. Pathol. 209, 474–483 (2006).
Harrington, L.E. et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 (2005).
Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005).
Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70 (2003).
Edgar, J.D. et al. Interferon-gamma receptor deficiency mimicking Langerhans' cell histiocytosis. J. Pediatr. 139, 600–603 (2001).
Patel, D.N. et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappa B and C/EBPbeta activation. J. Biol. Chem. 282, 27229–27238 (2007).
Acknowledgements
We thank S. Lebecque for fruitful scientific discussions on IL-17A autoantibodies, J.J. Pin (Dendritics SAS, http://www.dendritics.net) for technical discussions and IL-17A antibodies, O. Gillet, D. Gavhed, J. Lachuer and B. Blanquier for technical assistance, F. Archer and K. Gallay for the management of the Level 3 security laboratory, and M. Faure and G. Meiffren for critical reading of the manuscript. This work was supported by recurrent grants from the Institut National de la Santé Et de la Recherche Médicale, Université Claude Bernard de Lyon and grants from the Histiocytosis Association of America 2006, Fondation pour la Recherche Médicale DEQ2005120572, Émergence project of Rhône-Alpes Region, Ligue Contre le Cancer Ardèche Drome and Rhône, Institut National contre le Cancer-cancéropole 2004-2005, Association pour la Recherche sur le Cancer 3637, Association de Recherche sur la Polyarthrite and French Ministry of Research ACI8BC05H, the Italian Ministry of Health, Progetto di Ricerca Finalizzata 2004: “Istiocitosi e Tumori”, Associazione Italiana Ricerca Istiocitosi, the Swedish Children's Cancer Foundation, the Swedish Research Council, the Cancer and Allergy Foundation of Sweden and the Stockholm County Council (ALF project).
Author information
Authors and Affiliations
Contributions
C.D. conceived and wrote the initial study proposal and supervised the project. N.A. (immunohistological studies), S.O., A.S. and M.B. (Herpesvirus detections), and C.D., F.C., A.R. and C.S. made substantial contributions to acquisition of data with the technical assistance of O.A., M.F. and S.D. C.D., F.C., N.A., A.R., S.O., A.S. and M.B. carried out the data analysis. F.C. and J.T. conducted the sampling and clinical study of the rheumatoid arthritis patients, and M.A. (Table 1), J.-I.H. (Table 1) and R.M.E. (immunohistological samples) did likewise for the LCH patients. C.D. wrote the manuscript. C.R.-C., J.-I.H., M.A. and R.M.E. participated in the interpretation of the results and the editing of the manuscript.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–6, Table 1 and Supplementary Methods (PDF 12744 kb)
Rights and permissions
About this article
Cite this article
Coury, F., Annels, N., Rivollier, A. et al. Langerhans cell histiocytosis reveals a new IL-17A–dependent pathway of dendritic cell fusion. Nat Med 14, 81–87 (2008). https://doi.org/10.1038/nm1694
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1694
This article is cited by
-
Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis
Journal of Bone and Mineral Metabolism (2023)
-
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
Cell Communication and Signaling (2022)
-
Merkel cell polyomavirus and Langerhans cell neoplasm
Cell Communication and Signaling (2018)
-
Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Scientific Reports (2018)
-
Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis
Cell Communication and Signaling (2015)